Sentynl Takes U.S. Option on Mereo’s Alvelestat
Sentynl Therapeutics and Mereo BioPharma entered an option and license agreement for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease. Sentynl receives an option for U.S. commercialization and global manufacturing rights; Mereo retains rest-of-world commercial…
